THERAPY DOSSIER · th-6c32618bacdf

Avicennia schaueriana ethyl acetate leaf extract (As-AcOEt)

Nutraceutical

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 30780106 ↗2019Reported benefit

Gastroprotective effect of ethyl acetate extract from Avicennia schaueriana Stapf & Leechman and underlying mechanisms.

RatChemical/toxinWistarMale50, 100 and 200 mg/kgPre-treatment before ulcer induction

Model: HCl/ethanol-induced gastric ulcer

The extract reduced the ulcerative lesion index by 83.8, 88.5 and 86.9 per cent at 50, 100 and 200 mg/kg respectively, lowered myeloperoxidase and preserved gastric mucosa. Gastroprotection was reversed by L-NAME and carbenoxolone but not indomethacin, implicating nitric oxide and nonprotein sulfhy…

Extraction: extract · Supplied extraction confidence: 0.7. Machine-extracted fields require source verification.

Loading the evidence…